AI SummaryThe Albert Einstein College of Medicine has received funding from the NIH for a five-year project to develop vaccines and antibody-based therapies against emerging viruses. The project aims to build on lessons learned from COVID-19 by creating a base of critical knowledge about groups of similar viruses, allowing for the rapid development of specific… Continue reading NIH funds new research to combat emerging viruses
Tag: Immunotherapy
Experimental mRNA cancer vaccine shows potential for advanced stage cancer patients in Phase 1 trial
AI SummaryIn a Phase 1 trial, an experimental mRNA cancer vaccine (mRNA-4359) has shown promise in patients with advanced solid cancers such as lung cancer and melanoma. Nineteen patients received between one and nine doses of the vaccine, which created an immune response against cancer. Adverse events were generally mild, including fatigue, injection site pain,… Continue reading Experimental mRNA cancer vaccine shows potential for advanced stage cancer patients in Phase 1 trial
[ASAP] Design, Synthesis, and Bioevaluation of Novel NLRP3 Inhibitor with IBD Immunotherapy from the Virtual Screen
Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance
Abstract HER2-targeted therapies for patients with HER2+ breast cancer are rapidly evolving, offering a range of more complex and personalized treatment options. Currently, an array of anti-HER2 monoclonal antibodies, tyrosine kinase inhibitors and antibody–drug conjugates are administered, sometimes alongside chemotherapy or endocrine therapy, both in curative and palliative contexts. However, the heterogeneous nature of HER2+… Continue reading Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance
BMI’s relation to cancer therapy mortality risks not so straightforward
Researchers examined the impact of obesity in relation to treatment and mortality from data on over 500,000 lung cancer patients. This study suggests that immunotherapy may not be the optimal treatment for obese patients.
Tumor-induced B cell changes reveal potential biomarker for treatment response in triple negative breast cancer
AI SummaryThe article discusses a study that highlights tumor-induced B cell changes in the blood and bone marrow of triple negative breast cancer patients. The research identifies two distinct patterns of B cell abnormalities that could potentially be used as blood biomarkers to predict the response to standard chemotherapy and immunotherapy. This discovery could aid… Continue reading Tumor-induced B cell changes reveal potential biomarker for treatment response in triple negative breast cancer
Five key factors predict the response of cancer patients to immunotherapy
AI SummaryThis study identifies five factors that can predict cancer patients’ response to checkpoint inhibitors, validated in over 1,400 patients with various cancer types. These findings offer a way to interpret biomarkers for CPI response and could improve personalized cancer treatment in the future.Researchers have identified five independent factors that predict cancer patients’ response to… Continue reading Five key factors predict the response of cancer patients to immunotherapy
Using a molecular scissors to improve CAR-T cell therapy
AI SummaryResearchers have identified a new reason why CAR-T cell therapy fails in some cancer patients and are utilizing molecular scissors to improve the treatment’s outcomes. This discovery is leading to new strategies involving antibodies and gene editing to enhance the effectiveness of CAR-T cell therapy for patients.Researchers mined the molecular foundations of cancer and… Continue reading Using a molecular scissors to improve CAR-T cell therapy
Circumventing resistance within the Ewing sarcoma microenvironment by combinatorial innate immunotherapy
AI SummaryThis article discusses the use of combinatorial innate immunotherapy to overcome resistance within the Ewing sarcoma microenvironment. The study shows that a chimeric antigen receptor (CAR) NK cell targeting MCAM, combined with NKTR-255 (IL-15 agonist) and Magrolimab (CD47 blockade), significantly enhances NK cell cytotoxicity and macrophage phagocytic activity against ES cells. Results from in… Continue reading Circumventing resistance within the Ewing sarcoma microenvironment by combinatorial innate immunotherapy
DC-Derived Whole Cell Cytokines Nano-Regulator for Remodeling Extracellular Matrix and Synergizing Tumor Immunotherapy
You have access to this article Please wait while we load your content… Something went wrong. Try again?